Our top pick for
Tonix Pharmaceuticals Holding Corp is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Tonix Pharmaceuticals Holding employs 26 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$0.51 - $2.12|
|50-day moving average||$1.19|
|200-day moving average||$0.93|
|Wall St. target price||$3.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-8.25|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Tonix Pharmaceuticals Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tonix Pharmaceuticals Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tonix Pharmaceuticals Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Tonix Pharmaceuticals Holding shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||$0|
|Return on assets TTM||-56%|
|Return on equity TTM||-103.98%|
|Market capitalisation||$335.2 million|
TTM: trailing 12 months
There are currently 5.6 million Tonix Pharmaceuticals Holding shares held short by investors – that's known as Tonix Pharmaceuticals Holding's "short interest". This figure is 43.9% up from 3.9 million last month.
There are a few different ways that this level of interest in shorting Tonix Pharmaceuticals Holding shares can be evaluated.
Tonix Pharmaceuticals Holding's "short interest ratio" (SIR) is the quantity of Tonix Pharmaceuticals Holding shares currently shorted divided by the average quantity of Tonix Pharmaceuticals Holding shares traded daily (recently around 22.5 million). Tonix Pharmaceuticals Holding's SIR currently stands at 0.25. In other words for every 100,000 Tonix Pharmaceuticals Holding shares traded daily on the market, roughly 250 shares are currently held short.
However Tonix Pharmaceuticals Holding's short interest can also be evaluated against the total number of Tonix Pharmaceuticals Holding shares, or, against the total number of tradable Tonix Pharmaceuticals Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tonix Pharmaceuticals Holding's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Tonix Pharmaceuticals Holding shares in existence, roughly 20 shares are currently held short) or 0.0174% of the tradable shares (for every 100,000 tradable Tonix Pharmaceuticals Holding shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tonix Pharmaceuticals Holding.
Find out more about how you can short Tonix Pharmaceuticals Holding stock.
We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.
Tonix Pharmaceuticals Holding's shares were split on a 1:10 basis on 31 October 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.
Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $0.51 up to $2.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 1.3833. This would suggest that Tonix Pharmaceuticals Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.